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progression to a different chemotherapeutic antiblastic regimen. The 
treatment with Pemetrexed started after registration of Pemetrexed in 
Italy (May 2005) as an option for NSCLC after failure of the ﬁrst line 
regimen. All patients were required to take a premedication with folic 
acid and vitamin B12 supplements as well as corticosteroids.
Results: Data were collected from 160 patients, treated between May 
2005 and October 2006. The analysis was performed on the data up 
to January 31st 2007. All patients were affected by NSCLC, the most 
represented histology was adeno- (50.4%) and squamous cell carci-
noma (22.2%); mostly males, 117 ( 73.1%) versus 43 females (26.5%), 
and smokers (91.2%). 147 patients (91.9%) were affected by IV and 
13 (8.1%) by IIIB disease. The median age was 63.2 years (41-82); 41 
patients out of 160 (25.6%) were elderly,≥ 70 years. PS was 0 in 15% 
of the patients, 1 in 65.6%, 2 in 9%. 
Most of the patients were previously treated with a platinum-based che-
motherapy, except 6 (3.7%). The total number of cycles of Pemetrexed 
was 536, the median number of cycles of 3,3 per patient; 60 out of 
160, (37.5% ) received 3 cycles of Pemetrexed, 31 completed 6 cycles 
(19.4%); a few of them received more than 6 cycles (3 and 1 patient 
had 8 and 9 cycles respectively). About response, 17 patients (11.2%) 
showed a complete or partial response (CR and PR), 82 (51.2%) a pro-
gressive (PD) and 44 (27.5%) a stable disease (SD). The clinical beneﬁt 
(PR+CR+SD) was gained in 38.1% of patients.
4 patients out of 160 experienced a delay in chemo-administration: 
two patients due to urinary infection, and 2 patients due to pre-existent 
morbidities ( Crohn disease and ischaemic myocardial failure). Hema-
tological toxicities were mild, anemia G1 and G2 in 21 (13%) and 3 
patients (1.9%) respectively, leucopenia G3 in 3 (1.9%), thrombocy-
topenia G3 in 1 patient (0.6%); non-hematological toxicities consisted 
in fatigue (G1 in 11 and G2 in 9 patients, 6.9 and 5.6 % respectively), 
neurologic toxicitiy G2 in 3 patients (1.9%), stomatitis G2 in 2 patients, 
renal toxicity G2 in 1 patient and nausea G2 in 6 patients (3.7%).
The overall survival rate was assessed by Kaplan and Meier methods 
on 154 patients. The median survival, by the beginning of treatment 
with Pemetrexed, was 7.8 months.
Conclusion: Treatment of NSCLC with Pemetrexed in the second-line 
setting is feasible, active and tolerable and could represent an interest-
ing option for elderly or poor PS patients.
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Background: Survival of lung cancer is dismal particularly in de-
veloping countries. Chemotherapy may be one option in most cases. 
Cisplatin-based chemotherapy provides survival advantage, improved 
symptoms and quality of life (BMJ 1995, Rinaldi, M et al 2006) even 
in developing countries (Shajeem et al 2003). A number of new active 
drugs have been used. But cost factor is an important and perhaps the 
only constraint. We tried a relatively cheaper drug combination of 
irinotecan and cisplatin in patients of lung cancer (NSCLC and SCLC). 
Material and Method: Physical examination, hemogram, biochemistry, 
chest skiagram, and computed tomography (whenever possible) were 
done. Chemotherapy was administered on an outpatient basis consist-
ing of irinotecan 70mg/m2, and cisplatin (60 mg/m2) with proper hydra-
tion and anti-emetics every 28 days. 
Result: There were 197 histogically proven patients. 92 had small cell 
histology and 107 had non small lung cancer. 37 are still receiving 
chemotherapy. Only those who completed three or more cycles of che-
motherapy were included for the data analysis. Thus data was analyzed 
for 65 small cell and 95 non-small types. There were 43 extensive and 
22 limited stage small cell lung cancers. There were 130 males (35 to 
70 years; 30 females (age 45-65). The performance status ranged from 
70 to 100 (Kornofsky scale). 66 patients received local radiotherapy of 
20 to 50Gy. 116 patients completed 5 cycles of and 26 completed four 
cycles. The remaining received three cycles of chemotherapy at the 
time of data analysis. Complete response was observed in 19 (11.8%) 
and partial in 36(22.5%). Lesions remained stable ranging from 8 
weeks to 354 weeks (median of 29weeks; for small cell lung cancer - 
34 weeks and non-small cell lung cancer- 28weeks) before progression. 
At the time of data analysis the median survival has been 39+ weeks 
for those who completed ﬁve cycles. For others it has been 27+ weeks 
and they are still under follow up. 93 patients (58.1%) are surviving be-
yond 6 months and 27 patients (16.9%) are alive beyond one year and 
13 patients (8.1%) are still alive after 2 years. 52 patients gained weight 
during therapy with the mean increase of 4.2kg and 43 lost weight with 
a mean of 2.4 kg. Performance status improved in 68 and deteriorated 
in 33; in the remaining patients it was static. Side effects were minimal 
(alopecia, nausea, vomiting, diarrhea, skin changes and neuropathy) 
and not serious. 
Discussion: Irinotecan and cisplatin regimen is effective and well toler-
ated in patients with new, relapsed or refractory SCLC and NSCLC 
(Hong et al 2006; Jeong et al 2006; Hino et al 2006). A four-arm 
co-operative study reported that this combination has similar efﬁcacy 
compared to three other commonly used regimens (Ohe et al 2006). 
The problem of chemotherapy in developing countries is of afford-
ability of newer drugs. The cost of the present regimen is less than US$ 
100. Thus those who wish to take the advantage of chemotherapy, but 
could not afford high cost of therapy with taxanes/gemcitabine, irinote-
can and cisplatin should be offered to them for improved survival. 
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A randomized phase III study of carboplatin-gemcitabine (CG) 
versus carboplatin-paclitaxel (CP) in elderly patients (pts) with 
advanced non-small cell lung cancer (NSCLC) with emphasis on 
geriatric assessment and quality of life (QoL): The NVALT-3 study
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Background: Only a minority of elderly pts receives palliative 
chemotherapy (CT) for advanced NSCLC although they may beneﬁt 
from treatment. Concerns exist with regard to toxicity, especially when 
platinum-based CT is administered. Single agent CT is considered 
